Palisade Bio, Inc. (PALI)
The price, the headline numbers and the latest news, in one place.
Palisade Bio, Inc. (PALI) Stock Price, Analysis & Data
| Bid | 1.9 |
| Market Cap | 356M |
| Revenue (ttm) | 500K |
| Net Income (ttm) | -31.9M |
| 1.54 | |
| 0.66 | |
| 3.1 | |
| -7.3 | |
| P/B (ttm) | 2.92 |
| P/S (ttm) | 712.77 |
| Earnings Date | n/a |
| Ask | 2 |
| Volume | 1,086,552 |
| Avg. Volume (20D) | 2,833,225 |
| Open | 2.01 |
| Previous Close | 1.99 |
| Day's Range | 1.97 - 2.05 |
| 52-Week Range | 0.53 - 2.86 |
| Analyst | Strong<br>Buy |
| Price Target | 8 (292.16%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PALI
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research c...
Financial Performance
In 2025, Palisade Bio's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -16.78M, an increase of 16.23%.
Financial StatementsAnalyst Forecast
According to 9 analyst ratings, the average rating for PALI stock is "Strong Buy". The 12-month stock price forecast is 8, which is upside of 292.16% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.05 misses estimates by 0.00, with 92.75% YoY growth.
